Maureen Baehr, Vice President & Treasurer
Patricia Fast, Advisor
Margaret Liu, Advisor
Bill Snow, Secretary
Todd Summers, President
Mitchell Warren, Executive Director
Vice President & Treasurer
Maureen Baehr consults on strategy, philanthropy, knowledge management, and capacity building to both non-profit and for-profit organizations. She has more than two decades of experience in the private sector as a human resources executive for American Express and a management consultant to financial services clients including Lehman Brothers and Morgan Stanley. She has a Masters degree from Harvard University and is committed to HIV/AIDS and AIDS vaccines as part of her consulting and venture philanthropy work.
Elizabeth Bukusi's primary research focuses on sexually transmitted infections, reproductive health and HIV prevention, care and treatment. In 1995, she established the Research Care and Treatment Program (RCTP) at the Kenya Medical Research Institute (KEMRI), the goal of which is to enhance local capacity to conduct socio-behavioral and biomedical research and provide HIV care through training and infrastructure development. In addition to her substantial experience conducting research in Kenya as well as providing HIV care, and mentoring and training different cadres of health care and research personnel, she has an interest in ethics and the development of systems and structures for regulation of research in the institute and the country. She chairs the Scientific Steering Committee and has oversight of scientific regulation at KEMRI. She served on the MIRA (Diaphragm) Study and the CAPRISA 004 DSMB and currently chairs the Kenya HIV AIDS Research Coordinating Mechanism and also served on the WHO Department of Reproductive Health Scientific Technical Advisory Board (STAG).
Anne-Marie Duliege has extensive experience in infectious diseases and immunology and has long been associated with many aspects of the fight against AIDS. She initially focused on understanding the transmission of HIV from mother to child and then participated in the testing of HIV drugs and potential vaccines, first at Genentech and then at Chiron. In these endeavors, she has collaborated with the National Institute of Health, the Army, several companies, and many medical centers in the U.S. and around the world. Dr. Duliege is also a Clinical Assistant Professor in the Department of Pediatrics Rheumatology at the Lucille Packard Children's Hospital at Stanford. She also served as Chief Medical Officer at Affymax, a biopharmaceutical company focusing on peptide development. She has an MS in Epidemiology from Harvard School of Public Health, an MS in Biostatistics, a Doctorate in Medicine and a Board Certification in Pediatrics from Paris Hospitals.
Pat Fast is currently Senior Technical Advisor at the International AIDS Vaccine Initiative (IAVI). She joined IAVI from Aviron, a biopharmaceutical firm, where, as a Medical Director in the Clinical Research Department, she oversaw studies of vaccines for influenza and cytomegalovirus vaccines.. At the Division of AIDS at the US National Institute of Allergy and Infectious Diseases (NIAID), Dr. Fast led HIV vaccine clinical research as Associate Director for Vaccines and Prevention. In addition, she has worked at The Upjohn Company, Wellcome Research Laboratories and UCLA. She received her MD at Michigan State University, is board certified in pediatrics and also holds a PhD in immunology from the University of California at Los Angeles (UCLA). Dr. Fast has served on several national and international vaccine advisory committees, including the UNAIDS Vaccine Advisory Committee, the Enterprise Coordinating Committee, the US National Vaccine Advisory Committee and the Aeras Global TB Vaccine Foundation’s Vaccine Advisory Committee.
David Gold began as an AIDS treatment activist with ACT UP New York and co-founded AVAC. He has been active in HIV vaccine advocacy since 1992 when he convened a city-wide panel in New York to produce the first community-based paper on HIV vaccine research, titled Community Perspectives on HIV Vaccine Trials. An attorney by training, Gold was Director of Medical Information at Gay Men's Health Crisis (GMHC) and editor of GMHC's Treatment Issues newsletter from 1990 to 1995. He is the founding editor of the IAVI Report, the newsletter of the International AIDS Vaccine Initiative. David was also IAVI's founding Vice President for Policy and Public Sector Support. David currently serves as the principal of his own company, Global Health Strategies, an international consulting and communications firm.
Margaret Liu is an accomplished leader in the research and development of vaccine and immunization programs for infectious diseases, particularly HIV, and in the field of gene-based therapies. She served as Senior Director at Merck Research Laboratories in the Department of Virus and Cell Biology; Vice President of Vaccines Research and Gene Therapy at Chiron Corporation; Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation; Vice-Chairman of Transgene; Executive Vice-Chairman of the International Vaccine Institute in Seoul, Korea; a member of the Board and Advisory Council of the American Society of Gene Therapy; a member of the Board of Directors of the Keystone Symposia and the Immunogens and Antigen Processing Working Group of the HIV Enterprise; on the Advisory Board of the European AIDS Vaccine Integrated Project and the faculty of Europrise. She is currently Foreign Adjunct Professor at the Karolinska Institutet in Stockholm and Adjunct Full Professor at the University of California-San Francisco. She is the President-elect of the International Society of Vaccines, an International Advisor for the National Engineering Laboratory for Therapeutic Vaccines, China and on the International Scientific Advisory Board of the Jenner Institute.
Craig McClure is a leading global health consultant based in Toronto. From 2011-2016, he served as the HIV and AIDS Section Chief at UNICEF where he provided leadership and coordination of UNICEF’s work on HIV and AIDS at global level. Previously he coordinated the HIV treatment and care programme at the World Health Organization and was the senior adviser on the Treatment 20 initiative. Before that he was the Executive Director of the International AIDS Society (IAS) from 2004 to 2009. Craig has a background in political science, international relations, education and counseling. He began his work in HIV in the community sector in Canada, working for CATIE and then founding the consulting firm Health Hounds. In 2000 he began working at the global level, first with IAVI, then moved to Geneva in 2002. He has published and presented on his HIV work at international, regional and national conferences over the past 18 years. He is committed to approaches to ending the epidemic that balance the need for further research with expanded implementation of existing prevention tools, ethical and equitable access to care and treatment, and an end to stigma and discrimination against people living with HIV/AIDS and the marginalized communities that remain most vulnerable to HIV infection. In 2017, Craig was appointed an Officer of Order of Canada in recognition of his international leadership on HIV/AIDS, notably for his efforts to increase the availability of treatment options in the developing world.
Alex Menezes currently runs the Brazil office of Global Health Strategies. In addition, has been an AIDS advocate with Grupo Pela Vidda Rio de Janeiro since 1993. He was involved in organizing several national and international community focused AIDS vaccine meetings and other advocacy and educational activities in the field. Before moving to the US in early 2002 to join IAVI where he worked for over a decade in vaccine preparedness, he was a member of Brazil's National AIDS Vaccine Committee and part of the CAB for the HVTN site in Rio de Janeiro. Originally trained as a psychologist, Alex has two master's degrees in communications, one from the Federal University of Rio de Janeiro and a second one from New York University's Tisch School of the Arts.
Professor Helen Rees is the Executive Director of the Wits Reproductive Health and HIV Institute (RHI) of the University of Witwatersrand where she is also a Personal Professor in the Department of Obstetrics and Gynaecology. She is an Honorary Professor at the London School of Hygiene and Tropical Medicine (LSHTM) and serves on the LSHTM Visiting Committee, and is an Honorary Fellow of Murray Edwards College, Cambridge University. Professor Rees received her Medical Degree and a Master's in Social and Political Sciences from Cambridge University and is an alumnus of Harvard Business School. Professor Rees is one of South Africa's best known women scientists recognised for her contribution to national health policy and to global health. Her expertise spans reproductive health/STIs, HIV prevention and vaccines. She is the Chair of the South African Medicines Control Council, a member of the National Advisory Group on Immunisations and a member of the National Health Data Advisory and Coordination Committee. She is the Chair of the WHO Afro Regional Task Force on Immunization having previously chaired the WHO's global Strategic Advisory Group of Experts on Immunisation (SAGE) and remains on the SAGE Committee on the Global Vaccine Action Plan amongst other committees, and chairs of WHO's International Health Regulation's Emergency Committee on Polio. She also serves on several international scientific advisory committees. In 2006, she was the first person to receive the SA Department of Science and Technology's award for the Distinguished Scientist recognized for outstanding contribution to improving the quality of life of women. In 2001 Queen Elizabeth II made her an Officer of the British Empire for her contribution to global health.
Sarah J. Schlesinger MD is currently an Associate Professor of Clinical Investigation at The Rockefeller University and Senior Attending Physician at The Rockefeller University Hospital. As a 17-year-old in high school, Sarah went to work in the lab of Dr. Ralph Steinman and the late Dr. Zanvil Cohn at The Rockefeller University, just a few years after they published their discovery of dendritic cells. Some 40 years after the discovery, Schlesinger works to exploit the ability of dendritic cells to orchestrate the body's immune response, in order to develop new therapies for diseases ranging from cancer to HIV. Sarah graduated with honors from Wellesley College and obtained her medical doctorate from Rush Medical College in Chicago. Sarah trained in Anatomic Pathology at the New York Hospital/Cornell Medical Center, and has a distinguished research and teaching career: at SUNY Buffalo Medical School; led The Dendritic Cell section of The Division of Retrovirology at the Walter Reed Army Institute of Research ("WRAIR"); worked with the International AIDS Vaccine Initiative as a Scientist in Vaccine Research and Design; and returned to Rockefeller University in 2002 to lead clinical efforts to bring new HIV vaccine candidates developed at Rockefeller into the clinic. She is also co-chair of the Rockefeller Hospital's Institutional Review Board since 2003 and directs the Clinical Scholars training program and the education and training programs at The Rockefeller University Center for Clinical and Translational Science. In addition to the AVAC board, Sarah serves on the board Global Viral and the Hastings Center.
Bill Snow is Director of the Global HIV Vaccine Enterprise Secretariat, which represents the alliance of organizations conceived in 2003 to accelerate the search for an HIV vaccine, through mutual coordination, collaboration, knowledge sharing and increasing and optimizing resources to the field. At the Enterprise Secretariat since 2012, Bill had restructured Enterprise activities by reshaping the Strategic Convening function: with the Timely Topics in HIV Vaccines program, strategy roundtables and Enterprise Explorations with four focus areas. The Secretariat holds regular meetings of funders and clinical collaborators and work with industry advisors. The Secretariat is also hosting the new HIV Research for Prevention (R4P) Conference, the world's first and only scientific meeting dedicated exclusively to biomedical HIV prevention research. An advocate for HIV vaccines since 1990, he was instrumental in establishing national, local and global community advisory boards at the NIH clinical trial networks and continues to serves on many scientific leadership and review groups. Bill was a founder of AVAC and has written about the many challenges of developing AIDS vaccines, including major portions of the first several AVAC reports and the first edition of AVAC's widely used HIV Vaccines Handbook.
Todd Summers is currently a Senior Fellow at the Center for Strategic and International Studies Global Health Policy Center. Most recently, he had been working on behalf of the Global Fund's board of directors to help develop a new organizational strategy. He served as Vice Chair of the board's Policy and Strategy Committee. Prior to that, Summers served as Senior Advisor for Global Health at the ONE Campaign, where he helped lead their work to address urgent health issues facing people living in poor countries. From 2005 to 2010, he was a Senior Program Officer within the Global Health Policy and Advocacy team at the Bill & Melinda Gates Foundation. Before joining the staff in February 2005, Summers was president of Progressive Health Partners, a DC-based consulting firm specializing in public health policy he founded in 2000. From 1997 to 2000, Summers was the deputy director of the White House Office of National AIDS Policy. While there, he helped coordinate the nation's domestic HIV/AIDS work and to launch the administration's first international AIDS initiative. He also serves on the board of the US Fund for the Global Fund and Haiti's Matenwa Community Learning Center. He has a BA cum laude in Religion from Middlebury College.
Steve Wakefield is the External Relations Director for the NIH-sponsored HIV Vaccine Trials Network (HVTN) with the leadership group at the Fred Hutchinson Cancer Research Center in Seattle. As founder of The Legacy Project, Wakefield works with NIH’s HIV AIDS Network Coordination Office (HANC) on programs to increase minority involvement in trials. Wakefield currently serves on the planning bodies for CROI and the deFEAT HIV cure project which is part of the Martin Delany Collaboratives. He has been a member of the AVAC board since 1995. Wakefield is an HIV-negative health care advocate with over thirty years of involvement in projects that increase community participation, particularly for African Americans. He was the national chair of the NIH HIV Network for Prevention Trials (HIVNET) volunteer Community Advisory Board from 1995 to 1997, and former National CAB chair of the CPCRA, Community Programs for Clinical Research on AIDS, and community representative on the Executive Committee of the HIV Prevention Trials Network (HPTN). In 1999 he stepped down as Executive Director of The Night Ministry, an organization serving homeless and runaway youth in Chicago.
Mitchell Warren has been the Executive Director of AVAC since 2004. He was previously the Senior Director for Vaccine Preparedness at the International AIDS Vaccine Initiative (IAVI) and also spent four years as Vice President and Director of International Affairs for The Female Health Company (FHC), the manufacturer of the female condom, where he directed efforts to design and implement reproductive health programs that integrate the female condom, and he led global advocacy efforts for expanded commitment to female-initiated prevention methods. Mitchell also spent six years at Population Services International (PSI) designing and implementing social marketing, communications and health promotion activities in Africa, Asia and Europe, including five years running PSI's project in South Africa. Mitchell is a member of the board of directors of the Global HIV Vaccine Enterprise; the WHO-UNAIDS HIV Vaccine Advisory Committee; the Office of AIDS Research Advisory Council of the US National Institutes of Health (NIH); and Maloto. Mitchell has degrees in English and History from the University of Wisconsin-Madison and studied health policy at the Johns Hopkins University School of Hygiene and Public Health.